1,000 results on '"Rubbert-Roth A"'
Search Results
2. Stellenwert der Bildgebung in der Diagnose der Polymyalgia rheumatica
3. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
4. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
5. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study
6. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
7. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
8. Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry
9. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
10. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial
11. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies
12. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry
13. Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial
14. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies
15. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
16. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
17. POS0204 EFFECTIVENESS OF TNF INHIBITION IN VERY EARLY AXIAL SPONDYLOARTHRITIS (LESS THAN ONE YEAR OF AXIAL SYMPTOM DURATION): RESULTS FROM A LARGE NATIONAL OBSERVATIONAL COHORT
18. LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
19. POS0894 SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
20. POS0259 DOES BIOLOGIC DMARD RETENTION IN AXIAL PSORIATIC ARTHRITIS DEPEND ON THE MODE OF ACTION? COMPARISON OF TNF, IL-17, AND IL-23 INHIBITORS IN A LARGE OBSERVATION COHORT
21. POS1115 LOWER CD169 EXPRESSION ON MONOCYTES IN URINE THAN ON MONOCYTES IN PERIPHERAL BLOOD INDICATES SEVERITY OF RENAL INVOLVEMENT IN SLE PATIENT
22. POS0422 CHARACTERISTICS ASSOCIATED WITH LONG-TERM GLUCOCORTICOIDS USE IN PATIENTS WITH NEW ONSET POLYMYALGIA RHEUMATICA
23. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
24. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
25. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
26. Pulmonale Raumforderungen mit überraschendem Befund
27. Masses pulmonaires avec une découverte surprenante
28. ORAL SURVEILLANCE: Was hat sich an der Risikobeurteilung von JAK-Inhibitoren geändert?
29. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
30. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA
31. Gelenkschmerzen und ihre Differenzialdiagnose
32. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
33. Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis
34. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper
35. Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis
36. Lungenbeteiligung bei rheumatoider Arthritis
37. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
38. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
39. AB0200 IMPROVEMENT OF SLEEP IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS ACHIEVING REMISSION OR PAIN RELIEVE WITH UPADACITINIB: RESULTS FROM THE POST-MARKETING OBSERVATIONAL SLEERA STUDY
40. POS0827 CLINICAL OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO DISCONTINUED TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM ORAL SURVEILLANCE
41. POS0535 IS THERE A DECREASED RISK OF DEVELOPING CF ARTHROPATHY IN CF PATIENTS UNDERGOING TREATMENT THAT TARGETS THE F508DEL MUTATION?
42. POS0657 LONG-TERM SAFETY OF UPADACITINIB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS UP TO 5 YEARS
43. AB1335 INTAKE OF ACETAMINOPHEN SUPPRESSES ANTIVIRAL HUMORAL IMMUNE RESPONSES IN PATIENTS WITH RA FOLLOWING VACCINATION WITH ANTI SARS-CoV-2 mRNA BASED VACCINES
44. POS0547 RISK OF SARS-COV-2 INFECTION FOLLOWING THREE DOSES OF BNT162B2 OR MRNA-1273 IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES
45. Methotrexate in rheumatoid arthritis—another brick in the wall
46. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
47. A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
48. Methotrexate in rheumatoid arthritis—another brick in the wall
49. P135 Efficacy and safety of upadacitinib in TNFi inadequate responders with rheumatoid arthritis from three Phase 3 clinical trials
50. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.